CW August 2006
Volume 15Issue Number 8 August 2006 ISSN 10593802 Progression-Free Survival Better for ZD6474 Than Iressa in NSCLCA clinical trial testing the novel investigational agent ZD6474 (Zactima™, AstraZeneca) as a monotherapy in recurrent non-small cell lung cancer (NSCLC) revealed strong progression-free survival (PFS) improvements versus gefitinib (Iressa, AstraZeneca), but no survival advantage, according to an American Society of Clinical Oncology 2006 Annual Meeting presentation.
Go to Previous Page Go to Next Page Source & Additional Reading R. Natale, American Society of Clinical Oncology 2006 Annual Meeting presentation. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW August 2006Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
